Sartorius Announces Growth Targets#
Sartorius AG and its French subsidiary, Sartorius Stedim Biotech, have set formal mid-term profitability targets, marking their first structured financial commitments since a downturn in the bioprocessing industry. These targets will take effect starting in 2027.
Revenue Growth and Profit Margins#
Sartorius AG aims for an annual organic sales revenue growth of 8% to 11% in constant currencies, with an underlying EBITDA margin (Earnings Before Interest, Taxes, Depreciation, and Amortization) expansion of 50 to 75 basis points each year. In simpler terms, they expect to increase sales and improve profit margins steadily over the next few years.
Sartorius Stedim Biotech has set a slightly narrower growth target of 9% to 12% per year, with an EBITDA margin expansion of 60 to 85 basis points annually. Both companies anticipate outpacing their respective markets by 1% to 2% each year.
Division-Specific Projections#
The Bioprocess Solutions Division of Sartorius AG is projected to grow at a rate of 9% to 12% annually, with similar margin improvements. In contrast, the Lab Products & Services Division is expected to grow at a slower pace of 5% to 7%, with margin improvements of only 20 to 30 basis points. This indicates a significant difference in growth potential between the two divisions.
Industry Context and Challenges#
Both companies highlighted that global biopharma revenues have surpassed those of traditional therapies for the first time in 2025 and are expected to make up 57% of global pharmaceutical sales by 2030. CEO Michael Grosse emphasized the importance of innovation and reliability in the biopharma sector.
However, they also acknowledged increased uncertainty in forecasting due to geopolitical factors and changing trade conditions. All targets are expressed in constant currencies, and the absence of formal guidance for 2026 leaves some questions unanswered.
Sartorius AG employs over 14,000 people, while Sartorius Stedim Biotech has more than 10,200 employees.